|
시장보고서
상품코드
2078419
바이오 엔지니어링 단백질 의약품 시장 규모, 점유율 및 성장 분석 : 의약품 유형별, 적응증별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Bioengineered Protein Drugs Market Size, Share, and Growth Analysis, By Drug Type (Monoclonal Antibodies (mAbs), Recombinant Proteins (Insulin)), By Indication (Oncology, Autoimmune), By Distribution, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 바이오 엔지니어링 단백질 의약품 시장 규모는 2024년에 3,825억 2,000만 달러로 평가되었고, 2025년 4,078억 4,000만 달러에서 2033년까지 6,828억 5,000만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 6.62%를 기록할 전망입니다.
세계 바이오엔지니어링 단백질 의약품 시장은 개발 효율 향상과 비용 절감으로 이어지는 계산 모델링 및 스크리닝 기술의 발전에 힘입어 눈부신 성장을 이루고 있습니다. 이러한 발전 덕분에 규제 당국의 승인 절차가 신속해졌으며, 종양학, 자가면역 질환, 유전성 질환 등 다양한 분야에서 치료의 가능성이 확대되고 있습니다. 백혈병 치료용 이중 특이성 항체나 파브리병 치료용 효소 보충 요법 등 혁신적인 치료법이 급속히 도입되고 있는 점이 이러한 추세를 여실히 보여주고 있습니다. 그 결과, 투자자들의 틈새 바이오기술 기업에 대한 자금 지원이 늘어나고 있는 반면, 대형 제약사들은 이러한 최첨단 파이프라인을 활용하기 위한 제휴를 모색하고 있습니다. 이러한 역동적인 상호작용을 통해, 기존 지역과 신흥 지역 모두에서 시장의 강력한 성장 궤도가 확고히 자리 잡고 있습니다.
세계 바이오 엔지니어링 단백질 의약품 시장의 성장 요인
만성 질환 및 희귀질환의 유병률이 증가함에 따라, 각 제약사는 보다 표적화된 치료법을 모색하고 있으며, 바이오엔지니어링 단백질 의약품은 높은 특이성과 부작용 감소 덕분에 특히 주목을 받고 있습니다. 이러한 치료상의 이점으로 인해 의료 종사자들은 이러한 혁신적인 치료법을 도입하게 되었으며, 결과적으로 임상 적용 범위가 확대되고 시장 내 입지가 더욱 공고해지고 있습니다. 임상의들은 환자의 예후를 개선하고 부작용을 최소화하는 것을 목표로 하는 한편, 질환 관리의 개선과 입원율 감소를 통해 전 세계 의료 시스템에 장기적인 비용 대비 효과를 가져다준다는 점에서 이러한 치료법에 매력을 느끼고 있습니다. 이처럼 높아지는 관심이야말로 궁극적으로 전 세계 바이오 엔지니어링 단백질 의약품 시장을 주도하고 있습니다.
세계 바이오엔지니어링 단백질 의약품 시장의 제약 요인
세계 바이오엔지니어링 단백질 의약품 시장은 해당 바이오 제품의 복잡한 특성으로 인해 중대한 과제에 직면해 있습니다. 이러한 제품에는 세포 배양 최적화, 정제, 엄격한 품질 관리 조치와 같은 고도의 바이오프로세스이 필수적입니다. 이러한 복잡성으로 인해 전문적인 시설과 숙련된 인력이 필요하게 되어, 제조 비용 상승으로 이어지고 있습니다. 이러한 재정적 부담은 중소기업 시장 진입을 저해하고, 이러한 치료법의 가격 경쟁력을 제한할 가능성이 있습니다. 그 결과, 임상적 이점이 있음에도 불구하고 그 보급이 제한되고 말게 됩니다. 게다가 콜드체인 물류의 필요성과 규제 기준 준수가 시장의 확장성을 더욱 복잡하게 만들어, 이 분야의 전반적인 성장 가능성을 저해하고 있습니다.
세계 바이오엔지니어링 단백질 의약품 시장 동향
정밀 종양학의 발전이 혁신적인 치료법으로의 길을 열어가는 가운데, 전 세계 생체공학 단백질 의약품 시장에서는 뚜렷한 변화가 나타나고 있습니다. 각 기업은 종양 항원을 정확하게 표적화하기 위해 단백질 설계와 항체 개량에 점점 더 주력하고 있으며, 부작용을 최소화하면서 치료 효과를 높이고 있습니다. 생명공학 기업과 학술 기관 간의 협력이 점점 더 보편화되면서, 의약품 개발 과정이 효율화되고 혁신이 일어나기 쉬운 환경이 조성되고 있습니다. 또한, 임상의들이 맞춤형 치료 접근법을 도입함에 따라 치료 패러다임이 진화하고 있으며, 수익성이 높은 시장 기회가 창출되고 있습니다. 단백질 플랫폼에 대한 투자 확대는 표적 암 치료 분야의 변혁기를 알리는 것이며, 이 분야의 향후 성장을 주도할 것으로 보입니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 바이오 엔지니어링 단백질 의약품 시장 규모 : 약제 유형별
세계의 바이오 엔지니어링 단백질 의약품 시장 규모 : 적응증별
세계의 바이오 엔지니어링 단백질 의약품 시장 규모 : 유통별
세계의 바이오 엔지니어링 단백질 의약품 시장 규모 : 최종사용자별
세계의 바이오 엔지니어링 단백질 의약품 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSHGlobal Bioengineered Protein Drugs Market size was valued at USD 382.52 Billion in 2024 and is poised to grow from USD 407.84 Billion in 2025 to USD 682.85 Billion by 2033, growing at a CAGR of 6.62% during the forecast period (2026-2033).
The global bioengineered protein drugs market is experiencing significant growth, driven by advancements in computational modeling and screening techniques that enhance development efficiency and reduce costs. This progress enables quicker regulatory approvals and expands therapeutic possibilities in various fields such as oncology, autoimmune disorders, and genetic diseases. The swift introduction of innovative treatments, including bispecific antibodies for leukemia and enzyme replacement therapies for Fabry disease, highlights this trend. Consequently, investors are increasingly funding niche biotech firms, while larger pharmaceutical companies are seeking collaborations to tap into these cutting-edge pipelines. This dynamic interplay is solidifying a strong growth trajectory for the market across both established and emerging global regions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bioengineered Protein Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Bioengineered Protein Drugs Market Segments Analysis
Global bioengineered protein drugs market is segmented by drug type, indication, distribution, end-user and region. Based on drug type, the market is segmented into Monoclonal Antibodies (mAbs), Recombinant Proteins (Insulin, EPO), Fusion Proteins, Enzymes and Blood Factors. Based on indication, the market is segmented into Oncology, Autoimmune, Diabetes and Rare Diseases. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Hospitals, Specialty Clinics and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Bioengineered Protein Drugs Market
The increasing prevalence of chronic and rare diseases is prompting pharmaceutical companies to seek more targeted therapeutic solutions, with bioengineered protein drugs standing out due to their high specificity and reduced side effects. This therapeutic advantage encourages healthcare providers to adopt these innovative treatments, which in turn fosters broader clinical applications and deeper market integration. Clinicians are drawn to these modalities as they aim to improve patient outcomes and minimize adverse effects, all while offering long-term cost efficiency for health systems worldwide through improved disease management and decreased hospitalization rates. This growing interest ultimately propels the global bioengineered protein drugs market forward.
Restraints in the Global Bioengineered Protein Drugs Market
The Global Bioengineered Protein Drugs market faces significant challenges stemming from the intricate nature of its bioproducts, which necessitate advanced bioprocesses such as cell culture optimization, purification, and stringent quality control measures. This complexity demands specialized facilities and skilled personnel, leading to elevated manufacturing costs. Such financial burdens may deter smaller companies from entering the market and restrict the pricing competitiveness of these therapies, ultimately limiting their broader adoption despite their clinical advantages. Furthermore, the need for cold-chain logistics and adherence to regulatory standards further complicates market scalability, hampering overall growth potential in this sector.
Market Trends of the Global Bioengineered Protein Drugs Market
The Global Bioengineered Protein Drugs market is witnessing a notable shift as advancements in precision oncology pave the way for innovative therapeutics. Companies are increasingly focused on engineering proteins and modifying antibodies to precisely target tumor antigens, enhancing treatment efficacy while minimizing side effects. Collaborations between biotech firms and academic institutions are becoming more prevalent, streamlining drug development processes and fostering an environment ripe for innovation. Additionally, clinicians are embracing personalized treatment approaches, resulting in evolving treatment paradigms that create lucrative market opportunities. This growing investment in protein platforms signals a transformative period for targeted cancer interventions, driving future growth in the sector.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Bioengineered Protein Drugs Market Size by Drug Type & CAGR (2026-2033)
- Market Overview
- Monoclonal Antibodies (mAbs)
- Recombinant Proteins (Insulin, EPO)
- Fusion Proteins
- Enzymes
- Blood Factors
Global Bioengineered Protein Drugs Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Oncology
- Autoimmune
- Diabetes
- Rare Diseases
Global Bioengineered Protein Drugs Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
Global Bioengineered Protein Drugs Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Home Care
Global Bioengineered Protein Drugs Market Size & CAGR (2026-2033)
- North America (Drug Type, Indication, Distribution, End-User)
- US
- Canada
- Europe (Drug Type, Indication, Distribution, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Type, Indication, Distribution, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Type, Indication, Distribution, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Type, Indication, Distribution, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Roche (Genentech)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- UCB SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujifilm Diosynth Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
